Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Neutropenia grade ≥ 3 during treatment with docetaxel (DOC) is associated with an improved overall survival (OS): A retrospective analysis of the TAX327 phase III trial

Date

09 Oct 2016

Session

Poster display

Presenters

Alexander Meisel

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

A. Meisel1, D. Vogt2, R. de Wit3, J.S. de Bono4, O. Sartor5, M. Eisenberger6, F. Stenner-Liewen7

Author affiliations

  • 1 Department Of Internal Medicine - Hematology & Oncology, Stadtspital Waid, 8037 - Zurich/CH
  • 2 Clinical Trial Unit, University Hospital of Basel, 4031 - Basel/CH
  • 3 Medical Oncology, Erasmus University Medical Center, 3075EA - Rotterdam/NL
  • 4 Division Of Clinical Studies, Drug Development Unit, Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, SM2 5PT - Sutton/GB
  • 5 Medicine And Urology, Tulane Cancer Center, 70112 - New Orleans/US
  • 6 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 21287 MD - Baltimore/US
  • 7 Department Of Oncology, University Hospital of Basel, 4031 - Basel/CH
More

Resources

Abstract 3577

Background

We previously showed that mCRPC patients developing grade ≥3 neutropenia (NP) with cabazitaxel had a prolonged progression-free survival (PFS) and OS (Meisel EJC 2016; 56:93-100). A risk model combining the neutrophil-to-lymphocyte ratio (NLR) and grade ≥ 3 NP was built to distinguish patients with a poor, intermediate and good prognosis.

Methods

The prospective phase III trial TAX327 randomly assigned (1:1:1) chemonaïve mCRPC patients to DOC (30 mg/m2 for 5/6 weeks), DOC (75 mg/m2 every 3 weeks) or mitoxantrone 12 mg/m2 +prednisone 5 mg twice daily. Hematology was collected before each cycle. Prophylactic G-CSF was allowed in case of febrile neutropenia. This post-hoc analysis evaluates the influence of grade ≥ 3 NP and NLR on OS.

Results

OS in the DOC arms was significantly associated with the frequency of grade 3 3 NP (HR 0.89 [95% CI: 0.81 – 0.98], p = 0.02). There was an even stronger association (HR 0.82 [95% CI: 0.71 – 0.94], p = 0.005), when patients with at least one episode of grade 3 3 NP were analysed. Therefore we compared the OS of patients with multiple episodes of grade ≥3 NP to those with ≤ 1 episode of grade ≥3 NP and found a significantly prolonged OS for patients with multiple grade ≥3 NP episodes (HR 0.61 [95% CI: 0.39 – 0.97], p = 0.038). The median OS was 17.1 months for patients with a single episode of grade ≥3 NP, 18.2 months for those without grade ≥3 NP and 22.8 months for those with multiple episodes of grade ≥3 NP. The same association could be shown, when only the subgroup of patients treated with 3-weekly DOC, todays standard first line chemotherapy, was considered (HR 0.61 [95% CI: 0.38 – 0.96], p = 0.033). The biparametric risk model was applicable for mCRPC patients treated with 1st-line chemotherapy with DOC. The HR between risk category 0 (low NLR

Conclusions

This post-hoc analysis of TAX327 phase III trial suggests that the consecutive occurrence of grade ≥ 3 neutropenia with DOC is associated with an improved OS. Combining NLR and the occurrence of grade ≥ 3 neutropenia during taxane therapy may be useful to predict outcome.

Clinical trial identification

Legal entity responsible for the study

Alexander Meisel & Frank Stenner

Funding

Sanofi

Disclosure

A. Meisel: Received Travel grants, advisory boards and honoraria from Sanofi.

R. de Wit, J.S. de Bono, O. Sartor, M. Eisenberger: Advisory boards for Sanofi. Investigator.

F. Stenner-Liewen: Received Travel grants, advisory boards and honoraria from Sanofi. Corporate sponsored research.

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings